🇺🇸 HALO — Halozyme Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

103,63 USD

Máx. histórico

131,18

8 días

Caída desde máximo

-21,00%

Rango 52 semanas

61,23 – 134,00

Variación hoy

-15,72%

Cierre anterior

122,96

Rango de hoy

102,53 – 118,26

Volumen hoy

6.161.516

Peor caída histórica

-74,26%

05/06/2007 → 04/12/2008

Recuperado en 1154 días

Volatilidad anualizada ⓘ

58,09%

Información
Nombre completo
Halozyme Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
423
PER ⓘ
30,30 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
108,89 USD (puede no estar actualizado)
Primera cotización
16/03/2004
Precio actualizado
hace 1 hora
Sobre la empresa

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
17/01/2020 20,24 20,32 19,80 19,97 -0,79% 2,57% 1.679.900
16/01/2020 20,28 20,50 19,98 20,13 -0,49% 2,56% 2.274.600
15/01/2020 19,95 20,36 19,92 20,23 +1,76% 2,21% 2.726.800
14/01/2020 20,00 20,06 19,04 19,88 +5,91% 5,10% 2.731.300
13/01/2020 18,95 19,02 18,57 18,77 -1,16% 2,37% 1.781.000
10/01/2020 19,24 19,33 18,95 18,99 -1,35% 1,98% 1.584.200
09/01/2020 19,00 19,40 18,94 19,25 +4,34% 2,42% 1.726.100
08/01/2020 18,50 18,93 18,39 18,45 +3,54% 2,92% 2.031.300
07/01/2020 17,95 18,08 17,73 17,82 -1,27% 1,95% 623.900
06/01/2020 17,57 18,06 17,53 18,05 +1,80% 3,02% 1.076.300
03/01/2020 17,84 18,04 17,67 17,73 -2,04% 2,07% 1.032.700
02/01/2020 17,83 18,11 17,63 18,10 +2,09% 2,69% 1.626.700
31/12/2019 17,79 18,03 17,71 17,73 -0,56% 1,80% 859.900
30/12/2019 17,96 17,99 17,68 17,83 -0,83% 1,73% 897.600
27/12/2019 18,24 18,34 17,82 17,98 -1,69% 2,85% 791.800
26/12/2019 18,38 18,54 18,23 18,29 -0,60% 1,69% 601.700
24/12/2019 18,35 18,43 18,24 18,40 -0,43% 1,04% 404.800
23/12/2019 18,30 18,49 18,05 18,48 +1,65% 2,40% 970.700
20/12/2019 18,40 18,47 18,04 18,18 -0,93% 2,34% 2.492.200
19/12/2019 18,52 18,52 18,23 18,35 -1,02% 1,57% 1.151.600
18/12/2019 18,93 18,93 18,40 18,54 -2,06% 2,80% 1.332.300
17/12/2019 19,06 19,09 18,73 18,93 -0,79% 1,89% 1.324.800
16/12/2019 19,11 19,22 18,92 19,08 +0,53% 1,57% 1.361.600
13/12/2019 18,71 19,07 18,48 18,98 +1,39% 3,15% 1.256.100
12/12/2019 19,02 19,04 18,70 18,72 -0,11% 1,79% 936.000
11/12/2019 19,22 19,29 18,69 18,74 -2,45% 3,12% 1.182.000
10/12/2019 19,00 19,29 18,89 19,21 +0,95% 2,11% 1.632.900
09/12/2019 19,18 19,29 19,00 19,03 -0,68% 1,51% 1.657.500
06/12/2019 19,16 19,42 19,09 19,16 +0,52% 1,72% 958.200
05/12/2019 19,45 19,45 18,64 19,06 -2,11% 4,16% 2.403.900